Allogeneic hematopoietic stem cell transplantation for acute myeloblastic leukemia in first remission

Bondarenko S.N.

Institut detskoĭ onkologii, gematologii i transplantologii im. R.M. Gorbachevoĭ, SPbGMU im. akad. I.P. Pavlova

Semenova E.V.

B.V. Petrovsky Russian Research Center of Surgery ,Department of Acquired Heart Valvular Diseases, Moscow, Russia

Vavilov V.N.

Institut detskoĭ onkologii, gematologii i transplantologii im. R.M. Gorbachevoĭ, SPbGMU im. akad. I.P. Pavlova

Stancheva N.V.

Institut detskoĭ onkologii, gematologii i transplantologii im. R.M. Gorbachevoĭ, SPbGMU im. akad. I.P. Pavlova

Morozova E.V.

Otdelenie rentgenokhirurgicheskikh metodov diagnostiki i lecheniia FGBU "FTs SSKh" Minzdravsotsrazvitiia Rossii, Penza

Alianskiĭ A.L.

Institut detskoĭ onkologii, gematologii i transplantologii im. R.M. Gorbachevoĭ, SPbGMU im. akad. I.P. Pavlova

Babenko E.V.

Institut detskoĭ onkologii, gematologii i transplantologii im. R.M. Gorbachevoĭ, SPbGMU im. akad. I.P. Pavlova

Osipova N.É.

Institut detskoĭ onkologii, gematologii i transplantologii im. R.M. Gorbachevoĭ, SPbGMU im. akad. I.P. Pavlova

Zubarovskaia L.S.

Klinika "Institut detskoĭ gematologii i transplantologii im. R.M. Gorbachevoĭ" Sankt-Peterburgskogo gosudarstvennogo meditsinskogo universiteta im. I.P. Pavlova

Afanas'ev B.V.

Klinika "Institut detskoĭ gematologii i transplantologii im. R.M. Gorbachevoĭ" Sankt-Peterburgskogo gosudarstvennogo meditsinskogo universiteta im. I.P. Pavlova

Allogeneic hematopoietic stem cell transplantation for acute myeloblastic leukemia in first remission

Authors:

Bondarenko S.N., Semenova E.V., Vavilov V.N., Stancheva N.V., Morozova E.V., Alianskiĭ A.L., Babenko E.V., Osipova N.É., Zubarovskaia L.S., Afanas'ev B.V.

More about the authors

Journal: Therapeutic Archive. 2013;85(7): 18‑25

Downloaded: 568

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Bondarenko SN, Semenova EV, Vavilov VN, et al. . Allogeneic hematopoietic stem cell transplantation for acute myeloblastic leukemia in first remission. Therapeutic Archive. 2013;85(7):18‑25. (In Russ.)

Close metadata

Aim. To evaluate the efficiency of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloblastic leukemia in first remission depending on the regimens of conditioning, the source of a graft, and the characteristics of a donor and a recipient. Subjects and methods. In 66 treated patients, including from partially HLA-mismatched relatives (n=4), the efficiency of allo-HSCT from related donors (n=26) and unrelated donors (n=40), were compared. According to cytogenetic findings, 7 (11%), 31 (47%), and 10 (15%) patients belonged to low-, intermediate-, and high-risk groups, respectively. Results. Five-year overall survival (OS) and mortality associated with transplantation were 56 and 22% for allo-HSCT from related donors, 68 and 23% for that from HLA-matched donors, and 71 and 25% for that from partially HLA-mismatched donors, respectively (p=0.8 and p=0.7). The relapse risk after allo-HSCT from unrelated donors was significantly lower than after that from related donors (13 and 35%, respectively; p=0.8). Univariate analysis showed that the OS rates depended on the cytogenetic risk group (OS was 24 and 64% in the high- and intermediate-risk groups, respectively (p=0.027). The relapse risk in chronic graft-versus-host reaction (GVHR) and in grade 3 acute GVHR (p=0.01) was shown to be less than that in grades 1-2 acute GVHR (p=0.06). Conclusion. OS rates after allo-HSCT from related and unrelated donors were comparable and unrelated to the source of a graft, the regimen of conditioning, and other characteristics of a donor and a recipient.

Keywords:

allogeneic hematopoietic stem cell transplantation

acute myeloblastic leukemia

first remission

Authors:

Bondarenko S.N.

Institut detskoĭ onkologii, gematologii i transplantologii im. R.M. Gorbachevoĭ, SPbGMU im. akad. I.P. Pavlova

Semenova E.V.

B.V. Petrovsky Russian Research Center of Surgery ,Department of Acquired Heart Valvular Diseases, Moscow, Russia

Vavilov V.N.

Institut detskoĭ onkologii, gematologii i transplantologii im. R.M. Gorbachevoĭ, SPbGMU im. akad. I.P. Pavlova

Stancheva N.V.

Institut detskoĭ onkologii, gematologii i transplantologii im. R.M. Gorbachevoĭ, SPbGMU im. akad. I.P. Pavlova

Morozova E.V.

Otdelenie rentgenokhirurgicheskikh metodov diagnostiki i lecheniia FGBU "FTs SSKh" Minzdravsotsrazvitiia Rossii, Penza

Alianskiĭ A.L.

Institut detskoĭ onkologii, gematologii i transplantologii im. R.M. Gorbachevoĭ, SPbGMU im. akad. I.P. Pavlova

Babenko E.V.

Institut detskoĭ onkologii, gematologii i transplantologii im. R.M. Gorbachevoĭ, SPbGMU im. akad. I.P. Pavlova

Osipova N.É.

Institut detskoĭ onkologii, gematologii i transplantologii im. R.M. Gorbachevoĭ, SPbGMU im. akad. I.P. Pavlova

Zubarovskaia L.S.

Klinika "Institut detskoĭ gematologii i transplantologii im. R.M. Gorbachevoĭ" Sankt-Peterburgskogo gosudarstvennogo meditsinskogo universiteta im. I.P. Pavlova

Afanas'ev B.V.

Klinika "Institut detskoĭ gematologii i transplantologii im. R.M. Gorbachevoĭ" Sankt-Peterburgskogo gosudarstvennogo meditsinskogo universiteta im. I.P. Pavlova

List of references:

Yanada M., Matsuo K., Emi N., Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005; 103 (8): 1652-1658.
Parovichnikova E.N., Savchenko V.G., Klyasova G.A. i dr. Toksichnost' razlichnykh protokolov lecheniya ostrykh mieloidnykh leikozov vzroslykh: rezul'taty chetyrekh Rossiiskikh mnogotsentrovykh issledovanii. Ter arkh 2010; 7: 5-11.
Parovichnikova E.N., Klyasova G.A., Savchenko V.G. i dr. Pervye rezul'taty lecheniya ostrykh mieloidnykh leikozov vzroslykh po protokolu OML-01.10 nauchno-issledovatel'skoi gruppy gematologicheskikh tsentrov Rossii. Ter arkh 2012; 7: 10-15.
Koreth J., Schlenk R., Kopecky K.J. et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301 (22): 2349-2361.
Krauter J., Heil G., Hoelzer D. et al. Treatment of patients up to 60 years with high risk AML: final results of the AML SHG-Hannover 01/99 Trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2006; 108 (11): Abstr. 433.
Hubel K., Weingart O., Naumann F. et al. Allogeneic stem cell transplantation in adult patients with acute myeloid leukemia: to transplant or not to transplant? A Systematic review of international guidelines [abstract]. Blood 2009; 114 (22): 577-578. Abstr. 1419.
Basara N., Schulze A., Wedding U. et al. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia 2009; 23 (4): 635-640.
Weisdorf D.J., Anasetti C., Antin J.H. et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002; 99 (6): 1971-1977.
Szydlo R., Goldman J.M., Klein J.P. et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15 (5): 1767-1777.
Gupta V., Tallman M.S., He W. et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010; 116 (11): 1839-1848.
Chevallier P., Labopin M., Milpied N. et al. Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant 2012; 47: 1442-1447.
Popat U., de Lima M.J., Saliba R.M. et al. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant 2012; 47: 212-216.
Byrd J.C., Mrozek K., Dodge R.K. et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100 (13): 4325-4336.
Grimwade D., Hills R.K., Moorman A.V. et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116 (3): 354-365.
Gritsaev S.V., Martynkevich I.S., Abdulkadyrov K.M. i dr. Vozrast i kariotip - faktory riska u bol'nykh pervichnym ostrym mieloidnym leikozom. Klin onkogematol 2010; 4: 359-364.
Moore J., Nivison-Smith I., Goh K. et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007; 13 (5): 601-607.
Slovak M.L., Kopecky K.J., Cassileth P.A. et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96 (13): 4075-4083.
Gyurkocza B., Storb R., Storer B.E. et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 2859-2867.
Cornelissen J.J., van Putten W.L., Verdonck L.F. et al. Results of a HOVON/SAKK donor versus nodonor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middleaged adults: benefits for whom? Blood 2007; 109 (9): 3658-3666.
Suciu S., Mandelli F., de Witte T. et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102 (4): 1232-1240.
Sorror M.L., Giralt S., Sandmaier B.M. et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007; 110 (13): 4606-4613.
Parimon T., Au D.H., Martin P.J., Chien J.W. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006; 144 (6): 407-414.
Alyea E.P., Kim H.T., Ho V. et al. Impact of conditioning regimen intensity on outcome of Allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006; 12 (10): 1047-1055.
Ringden O., Labopin M., Ehninger G. et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27 (27): 4570-4577.
Khabori M.A., El-Emary M., Xu W. et al. Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation. Bone Marrow Transplant; 2011; 46 (4): 516-522.
Scott B.L., Sandmaier B.M., Storer B. et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20 (1): 128-135.

Close metadata